EUVIMEDEUVIMED entdecken
Crossref

Topical Roflumilast (Zoryve) for Plaque Psoriasis

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1668b ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Psoriasis, Dermatologic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisDermatologic AgentsHumansAminopyridinesBenzamidesCyclopropanesTreatment OutcomeAdministration, TopicalAdministration, CutaneousSeverity of Illness Index

Stichwörter der Autor:innen

DalirespDovonexDuobriiEnstilarEucrisaSoriluxTaclonexVecticalVtamaWynzoraZoryveadverse effectsbetamethasonecalcipotrienecalcitriol

Substanzen

RoflumilastAminopyridinesBenzamidesCyclopropanesDermatologic Agents

Zitieren

APA

(2023). Topical Roflumilast (Zoryve) for Plaque Psoriasis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668b

Vancouver

Topical Roflumilast (Zoryve) for Plaque Psoriasis. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668b

BibTeX
@article{euvimed2023,
  title = {Topical Roflumilast (Zoryve) for Plaque Psoriasis},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1668b}
}
Kostenlos starten →